199 related articles for article (PubMed ID: 37387523)
1. An overview of the preclinical discovery and development of tezepelumab for the treatment of asthma.
Matera MG; Ora J; Rogliani P; Cazzola M
Expert Opin Drug Discov; 2023; 18(9):951-963. PubMed ID: 37387523
[TBL] [Abstract][Full Text] [Related]
2. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
Menzies-Gow A; Wechsler ME; Brightling CE
Respir Res; 2020 Oct; 21(1):268. PubMed ID: 33059715
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Tezepelumab in Uncontrolled Severe Asthma: A Systematic Review of Randomized Controlled Trials.
Roy P; Rafa ZI; Haque SN; Tasha T; Arko SB; Agrawal H; Razu MI; Parisapogu A; Maisha S; Siddique MA; Abbasi FK; Shama N; Dev Nath S; Ghosh AS; Quader F
Cureus; 2022 Dec; 14(12):e32156. PubMed ID: 36601189
[TBL] [Abstract][Full Text] [Related]
4. Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma.
Marone G; Spadaro G; Braile M; Poto R; Criscuolo G; Pahima H; Loffredo S; Levi-Schaffer F; Varricchi G
Expert Opin Investig Drugs; 2019 Nov; 28(11):931-940. PubMed ID: 31549891
[No Abstract] [Full Text] [Related]
5. Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types.
Panettieri R; Lugogo N; Corren J; Ambrose CS
J Asthma Allergy; 2024; 17():219-236. PubMed ID: 38524099
[TBL] [Abstract][Full Text] [Related]
6. Positioning of Tezepelumab in Severe Asthma.
Miralles-López JC; Antolín-Amérigo D; García-Moguel I; Domínguez-Ortega J; Delgado-Romero J; Quirce S
J Investig Allergol Clin Immunol; 2024 Feb; 34(1):1-11. PubMed ID: 37812191
[TBL] [Abstract][Full Text] [Related]
7. Tezepelumab for asthma.
Nolasco S; Pelaia C; Scioscia G; Campisi R; Crimi C
Drugs Today (Barc); 2022 Dec; 58(12):591-603. PubMed ID: 36651067
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Potential Positioning of Tezepelumab in the Treatment of Severe Asthma.
Plaza V; Cañete C; Domingo C; Martínez Rivera C; Muñoz X
Open Respir Arch; 2023; 5(2):100231. PubMed ID: 37496871
[TBL] [Abstract][Full Text] [Related]
9. Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study.
Corren J; Karpefors M; Hellqvist Å; Parnes JR; Colice G
J Asthma Allergy; 2021; 14():1-11. PubMed ID: 33469316
[TBL] [Abstract][Full Text] [Related]
10. Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma.
Kurihara M; Kabata H; Irie M; Fukunaga K
Allergol Int; 2023 Jan; 72(1):24-30. PubMed ID: 36470789
[TBL] [Abstract][Full Text] [Related]
11. Sounding the alarmins-The role of alarmin cytokines in asthma.
Gauvreau GM; Bergeron C; Boulet LP; Cockcroft DW; Côté A; Davis BE; Leigh R; Myers I; O'Byrne PM; Sehmi R
Allergy; 2023 Feb; 78(2):402-417. PubMed ID: 36463491
[TBL] [Abstract][Full Text] [Related]
12. Tezepelumab: an anti-thymic stromal lymphopoietin monoclonal antibody for the treatment of asthma.
Shinkai M; Yabuta T
Immunotherapy; 2023 Dec; 15(17):1435-1447. PubMed ID: 37724378
[TBL] [Abstract][Full Text] [Related]
13. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial.
Diver S; Khalfaoui L; Emson C; Wenzel SE; Menzies-Gow A; Wechsler ME; Johnston J; Molfino N; Parnes JR; Megally A; Colice G; Brightling CE;
Lancet Respir Med; 2021 Nov; 9(11):1299-1312. PubMed ID: 34256031
[TBL] [Abstract][Full Text] [Related]
14. NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
Menzies-Gow A; Colice G; Griffiths JM; Almqvist G; Ponnarambil S; Kaur P; Ruberto G; Bowen K; Hellqvist Å; Mo M; Garcia Gil E
Respir Res; 2020 Oct; 21(1):266. PubMed ID: 33050934
[TBL] [Abstract][Full Text] [Related]
15. Baseline type 2 biomarker levels and response to tezepelumab in severe asthma.
Corren J; Pham TH; Garcia Gil E; Sałapa K; Ren P; Parnes JR; Colice G; Griffiths JM
Allergy; 2022 Jun; 77(6):1786-1796. PubMed ID: 34913186
[TBL] [Abstract][Full Text] [Related]
16. Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma.
Pelaia C; Pelaia G; Crimi C; Maglio A; Gallelli L; Terracciano R; Vatrella A
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922072
[TBL] [Abstract][Full Text] [Related]
17. Tezepelumab in Adults with Uncontrolled Asthma.
Corren J; Parnes JR; Wang L; Mo M; Roseti SL; Griffiths JM; van der Merwe R
N Engl J Med; 2017 Sep; 377(10):936-946. PubMed ID: 28877011
[TBL] [Abstract][Full Text] [Related]
18. Thymic Stromal Lymphopoietin and Tezepelumab in Airway Diseases: From Physiological Role to Target Therapy.
Bagnasco D; De Ferrari L; Bondi B; Candeliere MG; Mincarini M; Riccio AM; Braido F
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892164
[TBL] [Abstract][Full Text] [Related]
19. Tezepelumab in patients with allergic and eosinophilic asthma.
Caminati M; Buhl R; Corren J; Hanania NA; Kim H; Korn S; Lommatzsch M; Martin N; Matucci A; Nasser SM; Pavord ID; Domingo C
Allergy; 2024 May; 79(5):1134-1145. PubMed ID: 38146651
[TBL] [Abstract][Full Text] [Related]
20. SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma.
Wechsler ME; Colice G; Griffiths JM; Almqvist G; Skärby T; Piechowiak T; Kaur P; Bowen K; Hellqvist Å; Mo M; Garcia Gil E
Respir Res; 2020 Oct; 21(1):264. PubMed ID: 33050928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
